ONCOLOGY: Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Audio Journal of Oncology, December 10th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta Ibritumomab Provides Benefit in Patients with Follicular Lymphoma ANTON HAGENBEEK, University Medical Centre Utrecht REFERENCE: ABSTRACT 643, ASH 2007 For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.